Location: Warminster , PA 18974 +1 (215)-443-7000
2024
  • January - Launched Isosorbide Dinitrate and Hydralazine Hydrochloride 20mg/37.5mg tablets into US Market
2023
  • March - Successful FDA cGMP Inspection and five-product Prior Approval Inspection
  • October - Launched Posaconazole DR 100mg tablets into US Market.
  • November - Launched Maraviroc 150mg and 300mg tablets into US Market.
  • December - Launched Guanfacine 1mg and 2mg tablets into US Market
2022
  • February - Launched Selegiline HCl 5mg tablets into US Market. First product commercialized in the i3 label.
  • October - Launched Ranolazine 500mg and 1000mg extended-release tablets into US Market
2021
  • June - Successful FDA full, virtual GMP inspection.
  • September - Gained FDA ANDA approval for Selegiline HCl 5mg tablets.
2020
  • April - Gained FDA ANDA approval for Ramelteon 8mg tablets.
  • September - Gained FDA ANDA approval for Chlorzoxazone 375 and 750mg tablets.
2018
  • April - Filed first ANDA with the US FDA for a product for which there was formerly no generic alternative available.
  • December - Successful FDA Prior Approval and GMP inspection.
2016
  • January - Acquired a 150,000 square feet building in Warminster, PA.
  • December - Moved into the newly constructed facility with state of the art research and analytical laboratories, pilot & commercial manufacturing plants and warehouse.
2015
  • September - i3 Pharmaceuticals was formed with strong capital backing from private investors.
  • October - Leased laboratory space in Plymouth Meeting, PA.